Víkingur Ólafsson will return to Bourgie Hall for a pair of recitals featuring works by Bach, Beethoven, and Schubert. Known ...

"Compared with [J. S. Bach’s] six sonatas for violin without accompaniment, these violoncello solos are light and unpretending. Nevertheless, they are interesting, because they are Bach’s. The first ...

András Keller’s orchestra offers intensity, finesse and sheer dramatic sweep, from Tchaikovsky’s infernal tragedy to a ...

The all-new 2026 Honda Prelude is hitting showrooms and making a big splash. The sporty Honda coupe hasn't been offered in the US in 25 years, so enthusiasts have eagerly awaited its return. But there ...

The Prelude’s official pricing lands surprisingly close to the Civic Type R. Is it worth it? Well, that depends. The 2026 Honda Prelude starts at $43,195 for a single, fully loaded trim. Features ...

The first batch of new 2026 Honda Preludes for US deliveries arrived at west coast ports last week and customer deliveries are starting today. The new Prelude debuted as a concept at the 2023 Japan ...

At long last, we know how much the 2026 Honda Prelude is going to set buyers back if they want to get behind the wheel of the mildly hot hybrid coupe. Folks are going to have to hand over $43,195, ...

Since its official debut in September, the potential price of the upcoming 2026 Honda Prelude has been the subject of much debate, as the automotive corner of the internet tried to predict where the ...

Twenty-four years after it disappeared from the roads, the Honda Prelude was reborn last month at the Japan Mobility Show. We drove this iconic car that now has a hybrid heart but sportscar soul. The ...

The new Prelude was one of the year’s most anticipated new cars from the moment Honda announced it would revive the revered name on a new sporty coupe. Sales of the new Prelude begin in early 2026. My ...

Use BBC.com or the new BBC App to listen to BBC podcasts, Radio 4 and the World Service outside the UK.

It’s all change at Prelude Therapeutics. The precision oncology biotech is waving goodbye to its chief medical officer, pausing work on SMARCA2 degraders and selling a licensing option to Incyte. This ...